Tuesday, November 29, 2016
Galapagos NV says reports initiation of a phase 1 study in healthy volunteers with GLPG2737, a novel C2 corrector drug for cystic fibrosis.
Galapagos NV says topline results from this phase 1 study with GLPG2737 are expected in Q2 of 2017.
Galapagos NV says initiation of phase 1 study triggers a $10 million milestone payment from AbbVie.
Source : reuters.com
